ClinicalTrials.gov
ClinicalTrials.gov Menu

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01798238
Recruitment Status : Completed
First Posted : February 25, 2013
Last Update Posted : August 5, 2014
Sponsor:
Information provided by (Responsible Party):
Handok Pharmaceuticals Co., Ltd.

Brief Summary:
The study design of this trial is double blind, parallel-group, randomized, placebo controlled study

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: MP-513 Drug: Placebo Phase 3

Detailed Description:
  • Although many different oral antidiabetic agents are currently available, approximately 50% of treated Type 2 diabetic subjects do not reach currently accepted goals for HbA1c(Oral communication, American Diabetic Association, 2008)Subjects are frequently prescribed agents which can cause hypoglycemia, and/or weight gain.
  • In many countries, the most commonly prescribed primary oral diabetes drug that does not cause hypoglycemia or weight gain, is metformin, but metformin can cause gastrointestinal adverse drug reactions, nausea, vomiting, diarrhea, abdominal pain and loss of appetite and other symptoms, and rare but life-threatening lactic acidosis.
  • This decrease in the Power of Hydrogen Ions of the blood (<7.25) and the increase in blood lactate (> 5 mmol / L) is associated with a reduced kidney failure and if there is kidney impairment, decreased metformin clearance and thus accumulated metformin may occur lactic acidosis more frequently. Also there is inconvenience, such as adjusting metformin dose depending on patient's condition.
  • MP-513 is expected to be safely used as a treatment for type 2 diabetes because it has no risk of hypoglycemia and/or weight gain which are reported in pre-existing diabetes therapies and no inconvenience related to dose adjustment depending on patient's condition, and no cases of fatal side effects.
  • Furthermore the inhibitory effect on Dipeptidyl peptidase-IV was stronger and half-life was longer compared with other dipeptidyl peptidase-IV inhibitors in non-clinical trial, and blood glucose moderating effects are proven to be clinically significant in clinical trials conducted in Europe and Japan in that its development as a therapeutic agent for patients with type 2 diabetes is considered to be promising.
  • Based on these previous studies, the objective of this study is to investigate the efficacy and safety in subjects with type 2 diabetes mellitus that is not adequately controlled with exercise and diet.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 142 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III Double-blind, Parallel Group, Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of MP-513 Monotherapy in Patients With Type 2 Diabetes Mellitus
Study Start Date : November 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo group Drug: Placebo
Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day

Experimental: MP-513 group Drug: MP-513
form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day




Primary Outcome Measures :
  1. Glycosylated hemoglobin [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]

Secondary Outcome Measures :
  1. Mean fasting plasma glucose [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  2. Weight [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  3. Glycosylated hemoglobin <7.0% subject percent [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  4. Triglycerides [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  5. Homeostatic model assessment of insulin Resistance [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  6. Body mass index [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  7. Low Density Lipoprotein [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  8. High Density Lipoprotein [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  9. Cholesterol [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  10. Connecting peptide [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  11. Insulin [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  12. Homeostatic model assessment of beta-cell function [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]
  13. Glycosylated hemoglobin <6.5% subject percent [ Time Frame: Visit 1(Baseline Visit) vs Visit 7(week 24) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The subject is aged ≥18 years at signature of the informed consent form
  2. The subject has a documented diagnosis of Type 2 diabetes
  3. The subject's HbA1c is 7.0%≤HbA1c<10.0% at screening visit and run-in visit
  4. The subject's BMI is 20.0≤BMI≤40.0kg/m2
  5. The subject's fasting plasma glucose is <15 mmol/L (270 mg/dL)at screening visit and run-in visit
  6. The subject conducts a proper diet and exercise therapy for diabetes and its contents have not been changed for at least 8 week(56 days) at run-in visit(this does not apply to a subject with complications as as result of that exercise therapy is impossible)
  7. The subject has not used other diabetic medicine for at least 8 week(56 days) at run-in visit
  8. The subject is capable of giving informed consent, complying with the restrictions and requirements of the protocol

Exclusion Criteria:

  1. The subject has a history of Type 1 diabetes or a secondary form of diabetes(Diabetes caused by the pancreatic diseases, such as chronic pancreatitis, pancreatic cancer, hemochromatosis or the overproduction of hormones antagonistic to insulin, Cushing's syndrome, Basedow's disease, pheochromocytoma, drug, insulin receptor abnormalities)
  2. The subject has a history of MP-513 treatment
  3. The subject has a history of habitual and excessive alcohol abuse or drug abuse, or concerns
  4. The subject has a medical history of unstable angina, or heart failure(New York Heart Association class Ⅲ-IV) or any clinically significant ECG abnormalities such as ventricular tachycardia or a medical history of ventricular tachycardia
  5. The subject has participated in any other clinical study involving administration of an unlicensed medicinal product within 12 weeks prior to the screening visit or is participating any other clinical study
  6. The subject has received insulin within 12 months prior to the screening visit, with the exception of insulin therapy during hospitalization, insulin therapy for medical conditions not requiring hospitalization (<2 weeks duration) or use in gestational diabetes
  7. Female subjects whose pregnancy test is positive or who are pregnant, lactating, or are planning to become pregnant during the study
  8. The subject has serum creatinine >1.5 mg/dL(male) or >1.4 mg/dL(female)
  9. The subject has aspartate-amino-transferase (AST) and alanine-amino-transferase (ALT) >2.5 times the upper limit of normal (ULN)
  10. The subject has diastolic blood pressure >100 mmHg and/or systolic blood pressure >180 mmHg
  11. The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in the clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01798238


Locations
Korea, Republic of
Handok INC
Seoul, Gangnam-Gu, Korea, Republic of
Handok Pharmaceuticals CO. LTD
Seoul, Korea, Republic of
Sponsors and Collaborators
Handok Pharmaceuticals Co., Ltd.
Investigators
Principal Investigator: Sungwoo Park Kangbuk Samsung Hospital

Responsible Party: Handok Pharmaceuticals Co., Ltd.
ClinicalTrials.gov Identifier: NCT01798238     History of Changes
Other Study ID Numbers: MP_C302
First Posted: February 25, 2013    Key Record Dates
Last Update Posted: August 5, 2014
Last Verified: August 2014

Keywords provided by Handok Pharmaceuticals Co., Ltd.:
Type 2 Diabetes Mellitus / Dipeptidyl peptidase-IV inhibitors

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs